Is patella facet arthritis a contraindication to unicompartmental knee arthroplasty: Current concepts.

Journal and index pages often block iframe embedding. This reader keeps the evidence details in Orthonotes and leaves the source page one click away.

Abstract

[Indexed for MEDLINE] Conflict of interest statement: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Adolph Lombardi, Jr., MD reports a relationship with Zimmer Biomet that includes: consulting or advisory. Adolph Lombardi, Jr., MD (JIS Research Institute) reports a relationship with Total Joint Orthopedics that includes: consulting or advisory. Adolph Lombardi, Jr., MD (JIS Research Institute) reports a relationship with Firstkind that includes: funding grants. Adolph Lombardi, Jr., MD reports a relationship with Parvizi Surgical Innovations Research Institute that includes: equity or stocks and funding grants. Adolph Lombardi, Jr., MD (JIS Research Institute) reports a relationship with Recovery Rx that includes: funding grants. Adolph Lombardi, Jr., MD (JIS Research Institute) reports a relationship with SPR Therapeutics Inc that includes: funding grants. Adolph Lombardi, Jr., MD (JIS Research Institute) reports a relationship with Prescribe Fit that includes: equity or stocks and funding grants. Adolph Lombardi, Jr., MD reports a relationship with Smith and Nephew Inc that includes: funding grants. Adolph Lombardi, Jr., MD reports a relationship with SI-BONE Inc that includes: funding grants. Adolph Lombardi, Jr., MD reports a relationship with JIS Ventures that includes: equity or stocks. Adolph Lombardi, Jr., MD reports a relationship with Joint Development Corporation that includes: equity or stocks. Adolph Lombardi, Jr., MD reports a relationship with Operation Walk USA that includes: board membership. Adolph Lombardi, Jr., MD reports a relationship with Central Ohio Orthopaedic Management Company that includes: board membership. Adolph Lombardi, Jr. MD reports a relationship with Current Concepts in Joint Replacement that includes: board membership. Keith Berend, MD reports a relationship with Medacta USA INC that includes: speaking and lecture fees. Keith Berend, MD reports a relationship with Smith and Nephew Inc that includes: funding grants and speaking and lecture fees. Keith Berend, MD (JIS Research Institute) reports a relationship with Zimmer Biomet that includes: funding grants. Keith Berend (JIS Research Institute) reports a relationship with Total Joint Orthopedics that includes: funding grants. Keith Berend, MD (JIS Research Institute) reports a relationship with Firstkind that includes: funding grants. Keith Berend, MD (JIS Research Institute) reports a relationship with Parvizi Surgical Innovations Research Institute that includes: equity or stocks and funding grants. Keith Berend, MD (JIS Research Institute) reports a relationship with Recovery Rx that includes: funding grants. Keith Berend, MD (JIS Research Institute) reports a relationship with Prescribe Fit that includes: equity or stocks and funding grants. Keith Berend, MD reports a relationship with SPR Therapeutics that includes: funding grants. Keith Berend, MD (JIS Research Institute) reports a relationship with SI-BONE Inc that includes: funding grants. Keith Berend, MD reports a relationship with JIS Ventures that includes: equity or stocks. Keith Berend, MD reports a relationship with Joint Development Corporation that includes: equity or stocks. Adolph Lombardi, Jr., MD has patent with royalties paid to Zimmer Biomet. Adolph Lombardi, Jr., MD has patent with royalties paid to Innomed. Publications Editorial Boards (Adolph Lombardi, Jr., MD): Journal of Arthroplasty; Journal of Bone and Joint Surgery; Clinical Orthopaedics and Related Research; Journal of the American Academy of Orthopaedic Surgeons; Journal of Orthopaedics and Traumatology; Surgical Technology International; The Knee; The Bone & Joint Journal Publications Editorial Boards (Keith Berend, MD): Journal of Arthroplasty; Reconstructive Review. Todd Bertrand, MD, MBA; Patricia Melvin, MD, MBS have no known competing financial interests or personal relationships to declare that could have appeared to influence the work reported in this paper. 17. J Orthop Surg Res. 2025 Mar 17;20(1):289. doi: 10.1186/s13018-025-05592-8. Outcomes of patellofemoral joint arthroplasty: a systematic review of revision timelines and complication rates. Vella-Baldacchino M(1), Chughtai D(2), Kow J(2), Carr C(2), Coyle A(2), Farrow-Foster A(2), Russell J(2), Liddle AD(2). Author information: (1)Department of Surgery and Cancer, MSk Lab - Imperial College London, Sir Michael Uren Hub, 86 Wood Ln, London, W12 0BZ, UK. martinique.vella-baldacchino13@imperial.ac.uk. (2)Department of Surgery and Cancer, MSk Lab - Imperial College London, Sir Michael Uren Hub, 86 Wood Ln, London, W12 0BZ, UK. INTRODUCTION: This systematic review attempts to address survivorship of patellofemoral joint replacements, with conversion to a total knee arthroplasty (TKA) as an endpoint. METHODS: Survival estimates from multiple case series and national registries were pooled to calculate survival at 5, 10, 15 and 20 years, respectively. As a secondary outcome, the type and number of complications were recorded. A complication was defined as any any adverse event or unintended outcome that occurs as a result of the joint replacement, either during the immediate postoperative period or over the longer term. As arthroplasty registries do not report this information, this data was only included from publicly available series. RESULTS: 1015 eligible articles were identified, with 21 reporting survival and reasons for revision or complications. Data from registries were extracted. Using publicly available results from international joint registries, survival at 5 and 10 years were 90.30% (95% CI 88.32 to 92.27) and 82.23% (95% CI 78.90 to 85.56), respectively. However, long-term survivorship decreased to 73.74% (95% CI 69.12 to 78.37) and 72.68% (95% CI 69.58 to 75.53) at 15 and 20 years. CONCLUSION: Our pooled data, survival data from case series show similar results to international joint registries up to 10 years with a survival rate of 82.33%. These findings will be of use to patients and arthroplasty surgeons who require further information in order to predict how long patellofemoral joint replacements will last. © 2025. Crown. DOI: 10.1186/s13018-025-05592-8 PMCID: PMC11917147